-Reuters
Repare Therapeutics Reports Proof Of Concept For Lunresertib In Clinic, Initial Monotherapy Data From Phase 1 MYTHIC Clinical Trial And Early Insights From Ongoing Combination Trials
Findings from the ongoing Phase 1 MYTHIC study demonstrated a favorable and distinctive tolerability profile for monotherapy lunresertib
Monotherapy antitumor activity observed, including confirmed partial response and